Within the BIOMARKAPD study we have developed a health-economic simulation model to reflect the potential of CSF testing in clinical practice. You can download the model code below.
Publications of the model
- Handels R, Wimo A, Dodel R, Kramberger M, Visser PJ, Molinuevo J, Verhey F, Winblad B. Cost-utility of using Alzheimer's disease biomarkers in cerebrospinal fluid to predict progression from mild cognitive impairment to dementia. Journal of Alzheimer’s Disease. In press.
- Handels RLH, Vos SJB, Kramberger MG, Jelic V, Blennow K, van Buchem M, van der Flier W, Freund-Levi Y, Hampel H, Olde Rikkert M, Oleksik A, Pirtosek Z, Scheltens P, Soininen H, Teunissen C, Tsolaki M, Wallin AK, Winblad B, Verhey FRJ, Visser PJ. Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimers Dement. 2017 Aug;13(8):903-912. doi: 10.1016/j.jalz.2016.12.015.
Version history
13-02-2017: version used for generating the results for the publication in Journal of Alzheimer’s Disease.
Request a download URL